Cite
HARVARD Citation
Gibson, P. et al. (2016). Effectiveness and response predictors of omalizumab in a severe allergic asthma population with a high prevalence of comorbidities: the Australian Xolair Registry. Internal medicine journal. 46 (9), pp. 1054-1062. [Online].